Biocant - Technology Transfer Association

biocant.pt

BIOCANT Park is the first Portuguese venue entirely devoted to Biotechnology. Here, advanced Life Sciences knowledge and technology are developed and applied creating value in business initiatives. Through an audacious investment by the Municipality of Cantanhede and by the Center for Neuroscience and Cell Biology of Coimbra, and taking advantage of the last years’ national investment in Life Sciences, it was possible to set out an integrated development strategy to promote entrepreneurship and economic growth. The core of the Park is the R&D center – BIOCANT, Biotechnology Innovation Center – where specialized research teams use their built-up scientific competences to generate novel services and products. The scientific units of BIOCANT have committed staff and state-of-the-art equipment with high-throughput capacity.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Cell and Gene Therapy

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

news image

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Read More

METASTASIS BLOCKING ANTIBODY SHOWS PRECLINICAL PROMISE

Genetic Engineering and Biotechnology News | April 24, 2020

news image

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Read More

MedTech

BIOCYTOGEN LISTS ON THE MAIN BOARD OF HKEX, AIMING TO BECOME THE HEADSTREAM OF NEW DRUGS

Biocytogen | September 02, 2022

news image

Biocytogen Pharmaceuticals Co., Ltd. nnounced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of HK$ 25.22 per share. The net proceeds from the Global Offering will be approximately HK$ 471.1 million. Since its establishment in 2009, Biocyt...

Read More

EUROFINS DISCOVERY ANNOUNCES COLLABORATION WITH A SWISS-BASED BIOTECH COMPANY AMPHILIX AG

Eurofins Discovery | November 04, 2020

news image

Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage ...

Read More
news image

Cell and Gene Therapy

HEALIVA® ACQUIRES CRITICAL CELL THERAPY MANUFACTURING ASSETS FROM B. BRAUN

Healiva | November 22, 2022

Healiva®, a patient-centric company delivering life-enhancing precision medicine for patients with chronic and acute wounds, announced today the acquisition of critical manufacturing assets from B. Braun Medical AG Switzerland, an affiliate of German medical and pharmaceutical device company, B. Braun SE. The acquisition includes a qualified cell bank, which is essential for the GMP-compliant manufacturing of Healiva’s first cell therapy product, EpiDex®: an autologous epidermis de...

Read More
news image

METASTASIS BLOCKING ANTIBODY SHOWS PRECLINICAL PROMISE

Genetic Engineering and Biotechnology News | April 24, 2020

Investigators at the German Cancer Research Center in Heidelberg (DKFZ) and the Mannheim Medical Faculty of the University of Heidelberg have released data on an antibody they created that blocks a receptor that stimulates the formation of new blood vessels in tumors and metastasis. Findings from the new stud—published recently in EMBO Molecular Medicine through an article entitled “Preclinical validation of a novel metastasis‐inhibiting Tie1 function‐blocking antibody”—s...

Read More
news image

MedTech

BIOCYTOGEN LISTS ON THE MAIN BOARD OF HKEX, AIMING TO BECOME THE HEADSTREAM OF NEW DRUGS

Biocytogen | September 02, 2022

Biocytogen Pharmaceuticals Co., Ltd. nnounced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of HK$ 25.22 per share. The net proceeds from the Global Offering will be approximately HK$ 471.1 million. Since its establishment in 2009, Biocyt...

Read More
news image

EUROFINS DISCOVERY ANNOUNCES COLLABORATION WITH A SWISS-BASED BIOTECH COMPANY AMPHILIX AG

Eurofins Discovery | November 04, 2020

Eurofins Discovery, the leading provider of services and products to the drug discovery industry, announced a new collaboration with Amphilix AG, a Swiss-based biotech company, to support a program aimed at identifying a treatment modulating key disease mechanisms. Amphilix AG will take advantage of Eurofins Discovery's DiscoveryOne™ offering, an integrated drug discovery platform providing expert support to progress programs to preclinical development and beyond. Amphilix will engage ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us